FIELD: medicine.
SUBSTANCE: present invention relates to a class of cyclopropylamine compounds, namely to a compound of the formula (I), its pharmaceutically acceptable salt or its tautomer,
where values of f, r, e, p, m, n, R1, R2, R3, R4 and R6 are such as defined in the formula of the invention. Pharmaceutical compositions and the use of a compound of the formula (I) in the manufacture of LSD1 inhibitors and a drug for the treatment of lung cancer are also proposed.
EFFECT: obtaining new organic compounds that are inhibitors of lysin-specific demethylase 1 (LSD1).
29 cl, 8 tbl, 246 ex
| Title | Year | Author | Number |
|---|---|---|---|
| S1P1 AGONIST AND ITS APPLICATION | 2017 |
|
RU2754845C2 |
| PYRIDOPYRIMIDINE COMPOUNDS ACTING AS DOUBLE INHIBITORS OF mTORC 1/2 | 2018 |
|
RU2771201C2 |
| HYDROXYPURINE COMPOUNDS AND WAYS OF THEIR USE | 2015 |
|
RU2673458C1 |
| MACROCYCLIC COMPOUND WITH FUNCTIONS OF WEE1 INHIBITOR AND ITS APPLICATION OPTIONS | 2018 |
|
RU2783243C2 |
| FGFR INHIBITOR AND ITS MEDICAL USE | 2018 |
|
RU2771311C2 |
| HYDROXYPURINE COMPOUNDS AND USE THEREOF | 2016 |
|
RU2685417C1 |
| TRICYCLIC COMPOUNDS AFFECTING CRBN PROTEINS | 2019 |
|
RU2801068C2 |
| PDE4 INHIBITOR | 2017 |
|
RU2743126C2 |
| BICYCLIC COMPOUND AS RIP-1 KINASE INHIBITOR AND ITS USE | 2020 |
|
RU2800652C2 |
| DERIVATIVE BASED ON DIHYDROPYRIMIDO-RING AS HBV INHIBITOR | 2015 |
|
RU2693897C2 |
